MON-480 - Methadone-Associated Severe Hypoglycemia and Secondary Adrenal Insufficiency in A Patient with Opioid Use Disorder

Introduction
Methadone is an important therapy for opioid use disorder (OUD); however, its endocrine complications remain under-recognized. We report severe, persistent hypoglycemia associated with high-dose methadone occurring with secondary adrenal insufficiency, highlighting methadone's dual impact on glucose regulation and the hypothalamic-pituitary-adrenal (HPA) axis.

Case
A 55-year-old man with OUD, type 2 diabetes mellitus, chronic obstructive pulmonary disease, hypertension, and hyperlipidemia was admitted for COPD exacerbation complicated by acute hypoxic hypercapnic respiratory failure requiring mechanical ventilation. Methadone was initiated for opioid withdrawal at 20 mg daily and titrated to 80 mg twice daily (160 mg/day total). He developed new-onset, persistent hypoglycemia with nadir glucose of 56 mg/dL despite continuous enteral nutrition (2,620 kcal/day) and intravenous dextrose (D20 at 50 mL/hour).

Endocrine evaluation revealed inappropriately low morning cortisol (2.2 µg/dL, repeat 4.9 µg/dL) and ACTH (15 pg/mL), consistent with secondary adrenal insufficiency. Intravenous hydrocortisone (50 mg every 8 hours) stabilized glucose levels, allowing dextrose discontinuation. Methadone was subsequently reduced, and steroids were tapered to physiologic replacement dose.

Discussion
Methadone-associated hypoglycemia shows increased risk at doses ≥40 mg/day with threefold higher odds at doses >80 mg/day. The FDA notes cases may be dose-dependent, particularly in patients with diabetes. Proposed mechanisms include effects on insulin secretion and impaired counter-regulatory responses, with reports of hypoketotic, hyperinsulinemic hypoglycemia. Concurrently, Chronic opioid exposure suppresses the HPA axis, with secondary adrenal insufficiency reported in 9–29% of long-term users. The coexistence of impaired cortisol-mediated counter-regulation and methadone-related glucose lowering represents a clinically significant and potentially dangerous metabolic state. This case underscores the importance of vigilant glucose monitoring and adrenal evaluation in patients receiving high-dose methadone, particularly those with underlying glycemic disorders, and highlights an under-recognized endocrine complication in populations with high OUD prevalence.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*